Thoracic Oncologist Highlights Recent Pembrolizumab Data in NSCLC
November 19th 2018Pembrolizumab (Keytruda) has emerged as an effective frontline treatment option for select patients with metastatic non–small cell lung cancer, showing an overall survival advantage across 3 phase III clinical trials.
Read More